Zuoli Pharmaceutical announced that the company had previously acquired various micronutrient injection asset groups and continued to push for changes in the qualifications and rights of licensors to market agreed products. This time, the company received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. The marketing license holder for various micronutrient injections was changed from Hefei Future Pharmaceutical Development Co., Ltd. to Zhejiang Zuoli Pharmaceutical Co., Ltd., and the drug approval number remained unchanged. Warrant changes for other products of the Duowei Asset Group are being processed, and this approval is not expected to have a significant impact on the company's recent business performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.